Article
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Neurology - 24 Nov 2009
Dubbink H J, Taal W, van Marion R, Kros J M, van Heuvel I, Bromberg J E, Zonnenberg B A, Zonnenberg C B L, Postma T J, Gijtenbeek J M M, Boogerd W, Groenendijk F H, Smitt P A E Sillevis, Dinjens W N M, van den Bent M J
Abstract excerpt
BACKGROUND: Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas. Patients with high-grade astrocytomas with IDH1 or IDH2 mutations were reported to have a better survival, but it is unknown if this improved survival also holds for low-gra...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.